Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs ThredUp Inc (TDUP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs ThredUp Inc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.5 (market cap $31.07B), while ThredUp Inc trades at $2.19 (market cap $303.38M). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 102.4× ThredUp Inc's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while ThredUp Inc pays none. Which is the better fit depends on your goals.
| GEHC | TDUP | |
|---|---|---|
Market Cap | $31.07B | $303.38M |
Volume | 3,443,020 | 1,426,025 |
Sector | Health | Consumer Cyclical |
52-Week High | $88.16 | $9.38 |
52-Week Low | $59.48 | $2.12 |
Enterprise Value | $39.53B | $301.56M |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 29 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
ThredUp (TDUP) trades at $2.2, down 11.29% in the last session, with a bullish technical signal from moving averages but mixed oscillators. The company reported record Q2 2026 revenue of $90.8 million, up 17% year-over-year, but missed EPS estimates and cut full-year revenue guidance. Cash flow from operations improved to $10.65 million in 2025, though net income remains negative. Analyst consensus is 57% buy, with no sell ratings, but recent news highlights promotional headwinds and a securities investigation.
The outlook is cautious; revenue growth and high gross margins are positives, but persistent losses, weak guidance, and legal risks pose challenges. The stock's low price-to-sales ratio of 0.88 may attract value investors, yet profitability concerns and negative ROE of -36.76% underscore significant execution risk. Investors should weigh strong analyst support against fundamental weaknesses and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
